BIOCAUSE HEILEN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 20.9334 million yuan, a decrease of 71.96%

BIOCAUSE HEILEN PHARMA released its Q3 2025 report, with operating revenue for the first three quarters amounting to 319 million yuan, a year-on-year decrease of 4.52%. The net profit attributable to the parent company was 20.9334 million yuan, a year-on-year decline of 71.96%; the net profit after deducting non-recurring gains and losses was 543,800 yuan, a year-on-year decrease of 99.14%. The basic earnings per share were 0.05 yuan

BIOCAUSE HEILEN PHARMA: Febuxostat tablets have obtained a drug registration certificate

According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, for the drug Febuxostat Tablets. Febuxostat Tablets are a xanthine oxidase inhibitor, primarily used for the long-term treatment of hyperuricemia and gout patients (including urate-lowering treatment after acute attacks of gouty arthritis)

BIOCAUSE HEILEN PHARMA: Hydrochloride of Methoxychlorpromazine has received approval for the listing application of chemical raw materials

According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Metoclopramide Hydrochloride. Metoclopramide Hydrochloride is a dopamine receptor antagonist primarily used to relieve symptoms of nausea and vomiting, and it can also promote gastrointestinal motility to improve issues such as dyspepsia and delayed gastric emptying

BIOCAUSE HEILEN PHARMA released its half-year performance, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%

BIOCAUSE HEILEN PHARMA released its semi-annual report for 2025, with operating revenue of 235 million yuan, a year-on-year decrease of 2.93%; net profit attributable to the parent company was 18.5471 million yuan, a year-on-year decline of 72.92%. After deducting non-recurring gains and losses, the net profit was 4.4162 million yuan, a year-on-year decrease of 93.21%. The basic earnings per share were 0.06 yuan. The company plans to distribute 4.5 additional shares for every 10 shares to all shareholders and actively promote the implementation of fundraising investment projects, including the safety and environmental upgrade technical reform project for the hydrolysis and acidification position of ibuprofen raw materials and the construction of high-end pharmaceutical formulation internationalization projects

Pharmaceutical and medical stocks continue to strengthen, with FENGYUAN PHARMACEUTICAL hitting the limit up, Hengrui Pharma rising over 7%, and Haisco, BIOCAUSE HEILEN PHARMA, Yatai pharm, and Yirui Biologics also following suit